FDA Islatravir coverage for business development, investment, and market access teams
Today
High impact AnalysisJun 11, 2026
Merck and Gilead report mixed outcomes in lung cancer and HIV studies
HIV · 6 min
Dr. Sarah Mitchell Earlier
Critical impact NewsApr 22, 2026
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
FDA · HIV Treatment · 3 min
James Chen, PharmDPopular topics
- Drug Approvals 1,095 articles
- Clinical Trials 607 articles
- Regulatory Updates 653 articles
- FDA News 475 articles
- Press Releases 443 articles
- Oncology 439 articles
- Rare Diseases 139 articles
Explore intelligence
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways